Regulated Splicing of the α6 Integrin Cytoplasmic Domain Determines the Fate of Breast Cancer Stem Cells

Cell Reports

Volumn 7, Issue 3, 2014, Pages 747-761

  Goel, Hira Lal ^a   Gritsko, Tatiana ^a   Pursell, Bryan ^a   Chang, Cheng ^a   Shultz, Leonard D ^b   Greiner, Dale L ^a   Norum, Jens Henrik ^c   Toftgard, Rune ^c   Shaw, Leslie M ^a   Mercurio, Arthur M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ALPHA6 INTEGRIN; ALPHA6A INTEGRIN; ALPHA6B INTEGRIN; ALPHA6BBETA1 INTEGRIN; CD24 ANTIGEN; HERMES ANTIGEN; PACLITAXEL; UNCLASSIFIED DRUG; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 6; CD44V ANTIGEN; BMI1 PROTEIN; BMI1 PROTEIN, HUMAN; ESRP1 PROTEIN, HUMAN; RNA BINDING PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER STEM CELL; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RNA SPLICING; TRANSCRIPTION REGULATION; CELL FATE; ENZYME REPRESSION; MESENCHYME CELL; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; BREAST TUMOR; CHEMISTRY; CYTOLOGY; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INTEGRIN ALPHA6; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 1; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; RNA SPLICING; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899962484     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.03.059     Document Type: Article

References (51)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
2. Azzam D.J., Zhao D., Sun J., Minn A.J., Ranganathan P., Drews-Elger K., Han X., Picon-Ruiz M., Gilbert C.A., Wander S.A., et al. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. EMBO Mol Med 2013, 5:1502-1522.
3. Baccelli I., Trumpp A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 2012, 198:281-293.
4. Beck B., Driessens G., Goossens S., Youssef K.K., Kuchnio A., Caauwe A., Sotiropoulou P.A., Loges S., Lapouge G., Candi A., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478:399-403.
5. Brown R.L., Reinke L.M., Damerow M.S., Perez D., Chodosh L.A., Yang J., Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 2011, 121:1064-1074.
6. Bunker C.A., Kingston R.E. Transcriptional repression by Drosophila and mammalian Polycomb group proteins in transfected mammalian cells. Mol. Cell. Biol. 1994, 14:1721-1732.
7. Calcagno A.M., Salcido C.D., Gillet J.P., Wu C.P., Fostel J.M., Mumau M.D., Gottesman M.M., Varticovski L., Ambudkar S.V. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Natl. Cancer Inst. 2010, 102:1637-1652.
8. Cariati M., Naderi A., Brown J.P., Smalley M.J., Pinder S.E., Caldas C., Purushotham A.D. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int. J. Cancer 2008, 122:298-304.
9. Cooper H.M., Tamura R.N., Quaranta V. The major laminin receptor of mouse embryonic stem cells is a novel isoform of the alpha 6 beta 1 integrin. J. Cell Biol. 1991, 115:843-850.
10. De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13:97-110.
11. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
12. Douville J., Beaulieu R., Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009, 18:17-25.
13. Fiaschi M., Rozell B., Bergström A., Toftgård R. Development of mammary tumors by conditional expression of GLI1. Cancer Res. 2009, 69:4810-4817.
14. Gimond C., Baudoin C., van der Neut R., Kramer D., Calafat J., Sonnenberg A. Cre-loxP-mediated inactivation of the alpha6A integrin splice variant in vivo: evidence for a specific functional role of alpha6A in lymphocyte migration but not in heart development. J. Cell Biol. 1998, 143:253-266.
15. Goel H.L., Mercurio A.M. VEGF targets the tumour cell. Nat. Rev. Cancer 2013, 13:871-882.
16. Goel H.L., Pursell B., Standley C., Fogarty K., Mercurio A.M. Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling. J. Cell Sci. 2012, 125:497-506.
17. Goel H.L., Chang C., Pursell B., Leav I., Lyle S., Xi H.S., Hsieh C.C., Adisetiyo H., Roy-Burman P., Coleman I.M., et al. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov. 2012, 2:906-921.
18. Goel H.L., Pursell B., Chang C., Shaw L.M., Mao J., Simin K., Kumar P., Vander Kooi C.W., Shultz L.D., Greiner D.L., et al. GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med 2013, 5:488-508.
19. Groulx J.F., Giroux V., Beauséjour M., Boudjadi S., Basora N., Carrier J.C., Beaulieu J.F. Integrin α6A splice variant regulates proliferation and the Wnt/β-catenin pathway in human colorectal cancer cells. Carcinogenesis 2014, Published online February 6, 2014. 10.1093/carcin/bgu006.
20. Guo W., Pylayeva Y., Pepe A., Yoshioka T., Muller W.J., Inghirami G., Giancotti F.G. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006, 126:489-502.
21. Han H., Irimia M., Ross P.J., Sung H.K., Alipanahi B., David L., Golipour A., Gabut M., Michael I.P., Nachman E.N., et al. MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. Nature 2013, 498:241-245.
22. Hierck B.P., Thorsteinsdóttir S., Niessen C.M., Freund E., Iperen L.V., Feyen A., Hogervorst F., Poelmann R.E., Mummery C.L., Sonnenberg A. Variants of the alpha 6 beta 1 laminin receptor in early murine development: distribution, molecular cloning and chromosomal localization of the mouse integrin alpha 6 subunit. Cell Adhes. Commun. 1993, 1:33-53.
23. Hogervorst F., Kuikman I., van Kessel A.G., Sonnenberg A. Molecular cloning of the human alpha 6 integrin subunit. Alternative splicing of alpha 6 mRNA and chromosomal localization of the alpha 6 and beta 4 genes. Eur. J. Biochem. 1991, 199:425-433.
24. Hogervorst F., Admiraal L.G., Niessen C., Kuikman I., Janssen H., Daams H., Sonnenberg A. Biochemical characterization and tissue distribution of the A and B variants of the integrin alpha 6 subunit. J. Cell Biol. 1993, 121:179-191.
25. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108:1397-1402.
26. Lathia J.D., Gallagher J., Heddleston J.M., Wang J., Eyler C.E., Macswords J., Wu Q., Vasanji A., McLendon R.E., Hjelmeland A.B., Rich J.N. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6:421-432.
27. Lichtenberger B.M., Tan P.K., Niederleithner H., Ferrara N., Petzelbauer P., Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010, 140:268-279.
28. Lipscomb E.A., Simpson K.J., Lyle S.R., Ring J.E., Dugan A.S., Mercurio A.M. The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res. 2005, 65:10970-10976.
29. Liu S., Dontu G., Mantle I.D., Patel S., Ahn N.S., Jackson K.W., Suri P., Wicha M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006, 66:6063-6071.
30. Mercurio A.M. Laminin: multiple forms, multiple receptors. Curr. Opin. Cell Biol. 1990, 2:845-849.
31. Meyer M.J., Fleming J.M., Lin A.F., Hussnain S.A., Ginsburg E., Vonderhaar B.K. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010, 70:4624-4633.
32. Nagle J.A., Ma Z., Byrne M.A., White M.F., Shaw L.M. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol. Cell. Biol. 2004, 24:9726-9735.
33. Nieto M.A., Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin. Cancer Biol. 2012, 22:361-368.
34. Ocaña O.H., Córcoles R., Fabra A., Moreno-Bueno G., Acloque H., Vega S., Barrallo-Gimeno A., Cano A., Nieto M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22:709-724.
35. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P.G., Di Fiore P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
36. Pinto C.A., Widodo E., Waltham M., Thompson E.W. Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance. Cancer Lett. 2013, 341:56-62.
37. Sarrio D., Franklin C.K., Mackay A., Reis-Filho J.S., Isacke C.M. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012, 30:292-303.
38. Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 2012, 22:396-403.
39. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., Bell G., Guo W., Rubin J., Richardson A.L., Weinberg R.A. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
40. Shapiro I.M., Cheng A.W., Flytzanis N.C., Balsamo M., Condeelis J.S., Oktay M.H., Burge C.B., Gertler F.B. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 2011, 7:e1002218.
41. Shaw L.M., Lotz M.M., Mercurio A.M. Inside-out integrin signaling in macrophages. Analysis of the role of the alpha 6A beta 1 and alpha 6B beta 1 integrin variants in laminin adhesion by cDNA expression in an alpha 6 integrin-deficient macrophage cell line. J. Biol. Chem. 1993, 268:11401-11408.
42. Shaw L.M., Rabinovitz I., Wang H.H., Toker A., Mercurio A.M. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 1997, 91:949-960.
43. Tamura R.N., Cooper H.M., Collo G., Quaranta V. Cell type-specific integrin variants with alternative alpha chain cytoplasmic domains. Proc. Natl. Acad. Sci. USA 1991, 88:10183-10187.
44. Tanei T., Morimoto K., Shimazu K., Kim S.J., Tanji Y., Taguchi T., Tamaki Y., Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15:4234-4241.
45. Tennenbaum T., Belanger A.J., Glick A.B., Tamura R., Quaranta V., Yuspa S.H. A splice variant of alpha 6 integrin is associated with malignant conversion in mouse skin tumorigenesis. Proc. Natl. Acad. Sci. USA 1995, 92:7041-7045.
46. Vaillant F., Asselin-Labat M.L., Shackleton M., Forrest N.C., Lindeman G.J., Visvader J.E. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008, 68:7711-7717.
47. Vieira A.F., Ricardo S., Ablett M.P., Dionísio M.R., Mendes N., Albergaria A., Farnie G., Gerhard R., Cameselle-Teijeiro J.F., Seruca R., et al. P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer. Stem Cells 2012, 30:854-864.
48. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10:717-728.
49. Warzecha C.C., Jiang P., Amirikian K., Dittmar K.A., Lu H., Shen S., Guo W., Xing Y., Carstens R.P. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J. 2010, 29:3286-3300.
50. Yae T., Tsuchihashi K., Ishimoto T., Motohara T., Yoshikawa M., Yoshida G.J., Wada T., Masuko T., Mogushi K., Tanaka H., et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012, 3:883.
51. Yang X., Pursell B., Lu S., Chang T.K., Mercurio A.M. Regulation of beta 4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition. J. Cell Sci. 2009, 122:2473-2480.